Immuron is progressing with a new Investigational New Drug (IND) application to the Food and Drug Administration (FDA) to initiate the clinical...
3 weeks ago

Immuron (NASDAQ: IMRN) reported significant progress across multiple projects in their latest shareholder update. The company is set to exceed A...
3 weeks ago

Immuron hosts a proprietary technology platform that develops specific oral antibodies to address urgent medical needs. · Immuron is a publicly...
4 months ago

The company released its March quarter results for 2025. During the quarter, Immuron Limited (NASDAQ:IMRN) surpassed AUD$5 million in a fiscal...
1 month ago

The latest update is out from Immuron Limited ( ($AU:IMC) ). Immuron Limited has announced a proposed issue of 135800 fully paid ordinary securities,...
3 weeks ago

Immuron reports record Travelan sales ... Immuron Ltd (NASDAQ:IMRN), a biopharmaceutical company, has announced its highest ever sales for its...
2 months ago

Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in...
3 months ago

Immuron Letter to Shareholders: Projects Update | IMRN Stock News · Immuron (IMRN, Financial) projects over A$7 million in sales for the current...
3 weeks ago

Immuron Ltd (NASDAQ:IMRN), an Australian pharmaceutical company, has submitted an application for the quotation of securities on the...
3 weeks ago

Immuron Limited ( ($AU:IMC) ) has shared an announcement. Immuron Limited has issued 116680 ordinary shares without disclosure under Part...
3 weeks ago